International Journal of Hematology

, Volume 89, Issue 5, pp 577–583 | Cite as

Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience

  • Yutaka ShimazuEmail author
  • Kenji Notohara
  • Yasunori Ueda
Original Article


The introduction of rituximab for diffuse large B-cell lymphoma (DLBCL) has improved the disease’s overall prognosis. However, relapse in the central nervous system (CNS) is still an issue. We investigated the prognosis and risk factors of CNS recurrence in DLBCL. A total of 403 patients who were diagnosed with DLBCL without CNS involvement between January 1996 and April 2007 at our institution were included in the study. Subsequently, 42 experienced CNS relapse. Clinical information was gathered by chart review. The median disease-free interval to CNS relapse was 625 days. The mean survival periods after relapse in the cases with CNS and extra-CNS involvement were 513 and 1,615 days, respectively (P = 0.0004). Multivariate analysis identified age >60 years (P = 0.031), involvement in two or more extranodal sites (P = 0.040), bone marrow involvement (P = 0.036), an elevated serum lactate dehydrogenase (LDH) level (P = 0.016), and treatment without rituximab before CNS relapse (P = 0.027) as independent predictors of CNS relapse. We have shown that cases of DLBCL occurring in advanced age, involving two or more extranodal sites or the bone marrow, or showing an elevation of LDH have a higher risk of CNS relapse. Rituximab may prevent CNS relapse by reducing the recurrence of DLBCL at all sites. An effective CNS prophylaxis strategy should be determined according to the risk assessment of CNS relapse.


CNS relapse Diffuse large B-cell lymphoma Rituximab Risk factors Retrospective study 



This study was conducted at Kurashiki Central Hospital. We would like to thank all the clinicians and patients who contributed to this research.


  1. 1.
    Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Eng J Med. 2002;346:235–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33.PubMedCrossRefGoogle Scholar
  4. 4.
    van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178–84.PubMedGoogle Scholar
  5. 5.
    Hollender A, Kvaloy S, Lote K, Nome O, Holte H. Prognostic factors in 140 adult patients with non-Hodgkin’s lymphoma with systemic central nervous system (CNS) involvement: a single centre analysis. Eur J Cancer. 2000;36:1762–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin’s lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma. 2002;43:587–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111:1085–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006;20:319–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Secondary central nervous system lymphoma. Int J Hematol. 2006;84:128–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15:129–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin’s lymphoma. Leuk Lymphoma. 2002;43:1783–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer. 2002;95:576–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18:541–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients (Groupe d’Etudes des Lymphomes de l’Adulte). Ann Oncol. 2000;11:685–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Boehme IV, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma: a survey of 1, 693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149–57.PubMedCrossRefGoogle Scholar
  16. 16.
    Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol. 2002;13:1099–107.PubMedCrossRefGoogle Scholar
  17. 17.
    Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma: a multivariate analysis. Acta Oncologica. 1996;35:703–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107–14.PubMedCrossRefGoogle Scholar
  19. 19.
    Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol. 2005;131:193–200.PubMedCrossRefGoogle Scholar
  20. 20.
    Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, et al. Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki. 1994;35:635–41.PubMedGoogle Scholar
  21. 21.
    Takasu S, Wakabayashi T, Kajita Y, Hatano N, Hatano H, Usui T, et al. Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma. No Shinkei Geka. 2000;28:789–94.PubMedGoogle Scholar
  22. 22.
    Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM, et al. Effectiveness of second-line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma. 2007;48:1332–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18:3633–42.PubMedGoogle Scholar
  24. 24.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. High-dose therapy and autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl J Med. 1995;333:1540–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997;16:901–10.PubMedCrossRefGoogle Scholar
  26. 26.
    Kaplan EI, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;55:457.CrossRefGoogle Scholar
  27. 27.
    Collet D. Modelling survival data in medical research. Boca Raton: Chapman & Hall/CRC; 1999. p. 80–1.Google Scholar
  28. 28.
    Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24:1281–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Kikuchi A, Kawada H, Iwaki Y, Machida S, Tsuchiya T, Fukuda R, et al. Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma. Rinsho Ketsueki. 2004;45:1255–7.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Yutaka Shimazu
    • 1
    • 2
    Email author
  • Kenji Notohara
    • 3
  • Yasunori Ueda
    • 1
  1. 1.Department of Hematology/OncologyKurashiki Central HospitalOkayamaJapan
  2. 2.Department of Hematology/Oncology, Graduate School of MedicineKyoto UniversitySakyo-kuJapan
  3. 3.Department of PathologyKurashiki Central HospitalOkayamaJapan

Personalised recommendations